Top Stories
The treatment was previously approved for pharmacologically-induced mydriasis in 2023.
The decision to discontinue the trial was due to "strategic considerations."
The EMA's Committee for Medicinal Products for Human Use also recommended approval of Revolution Medicines' pancreatic cancer drug.
The funding will help the biotech move its two lead programmes into the clinic for autosomal dominant polycystic kidney disease in 2027 and 2028, respectively.
The biotech's shares climbed roughly 25% during its first day of trading on Friday.
Conference News
PHILADELPHIA--(BUSINESS WIRE)-- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing T cell-based immunotherapies that contain checkpoint modifiers, today announced that an abs...
– Presentation will provide interim Phase 2 clinical data on HLX79/E-602, a first-in-class human sialidase enzyme therapeutic, in patients with membranous nephropathy –WALTHAM, Mass.--(BUSINESS WIRE)-...
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
First global Ris-Rez data to show positive anti-tumour activity in relapsed extensive-stage small-cell lung cancer Late-breaking Mo-Rez data will demonstrate clinically meaningful and durable activity...
16 October, 2026 12:45Positive CHMP opinion based on Phase 3 CORE and CORE2 results, demonstrating a statistically significant placebo-adjusted mean reduction of up to 72% in triglyceride levels and a...
